The 14th meeting of the 10th board of directors and the 9th meeting of the 9th board of supervisors held to review and approve the annual work report and other relevant proposals
Release time:
2020-07-31
News from our newspaper 4# April 24 , Chairman Jiang Xiaomeng of the Group Company presided over the 14 meeting of the 10th Board of Directors of the Company, deliberated and approved 2019 Board of Directors Report, 2019 General Manager Business Report, 2019 Annual Report and other 14 related reports and proposals.
General Manager's report points out that 2019 is the first year of the implementation of the group's new five-year strategic development plan (2019-2023 ) and the new three-year business plan (2019-2021) for each business sector. The management team focuses on the general working policy of "innovation and reform, integration and promotion, scientific layout and steady development, orderly carry out all kinds of operation and management work, and better fulfill the business objectives set by the board of directors at the beginning of the year. In the whole year, the company realized a total operating income of 35.48 .8 billion yuan, up 5.51% year on year. Net profit attributable to shareholders reached 7.25 .2 billion yuan, earnings per share reached 2.11 yuan, up 23.14% year on year, reaching a new record high. At the end of the year, total assets reached 54.75 .8 billion yuan, up 11.71% year on year; net assets attributable to shareholders were 37.89 .2 billion yuan, up 19.81% year on year.
During the reporting period, the company's two main businesses have achieved great development, benefiting from the further promotion of supply-side structural reform, 2019 cement industry operation is generally stable, industry efficiency further improved. During the reporting period, the company made new progress in the construction of cement projects, completed the acquisition, capital increase and name change of Guizhou Mingchuan (Guizhou Huangping Jianfeng Cement Co., Ltd.), and continued to invest in the construction of its new dry cement production line with a daily output of 4500 tons (with waste heat power generation). During the reporting period, the company completed the construction investment of 4.47 .4 billion yuan, and the project progressed smoothly; yunnan Jianfeng invested ,500 yuan to participate in the establishment of Yunnan Jianfeng Da Zhan Cement Co., Ltd., accounting for 10% of its shares, further expanding the company's cement business segment. During the reporting period, Daye Peak and Yunnan Peak continued to carry out in-depth "three reductions and three improvements" activities, steadily implemented standardized management, vigorously introduced advanced and applicable technologies to implement technological transformation, and continuously improved the labor productivity of enterprises while strictly controlling production costs. The leading position in the regional market has been further consolidated and enhanced, 2019 Daye Peak realized net profit 2.98 .2 billion yuan, Yunnan Peak realized net profit 2.71 .4 billion yuan, the company's cement sector operating performance reached a new record high.
2019 was a year of constant volatility and accelerated differentiation in the pharmaceutical market, with the introduction of new pharmaceutical policies to promote the development of the entire industry in the direction of concentration, innovation and high quality. During the reporting period, in order to fully cope with the changes in the industry and enrich the company's product line, Jianfeng Pharmaceutical further strengthened its product research and development and innovation. More than 20 research projects were under development, which were respectively in various stages of preclinical research, clinical research, pre-production research or production application. Olopatadine Hydrochloride Eye Drops obtained the drug registration approval and was put on the market. Paroxetine Hydrochloride Tablets passed the consistency evaluation smoothly, the drug supplement application approval was obtained in , 2020, , , 3, and July; Complete the registration and consistency evaluation declaration of cefmenoxime hydrochloride raw materials and injections; Complete the registration and filing of imatinib mesylate raw materials and tablet registration declaration. 2019 , Jianfeng Pharmaceutical and its subsidiaries made new progress in a number of technological transformation and engineering construction. The construction of the annual production of 20 .9 billion solid preparations (internationalization) project in Jinxi Production Base of Jianfeng Pharmaceutical is progressing smoothly. The project is listed as a major industrial project in Zhejiang Province in 2019 and a key technological transformation project in Jinhua City in 2020 ; the implementation of Anhui Beika and Anhui Zhongwang Phase II technological transformation projects will upgrade and on the basis of their existing products to become the company's comprehensive research and development and production base for raw materials, pharmaceutical intermediates and pesticides, and actively promote the industrial upgrading strategy of the integration of peak pharmaceutical raw materials and preparations. On the day of
9 , and reviewed and approved related reports and proposals such as the work report of the board of supervisors 2019 , the financial final accounts report of 2019 , and the profit distribution plan of 2019 . (Remaining Fruit)
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page